Merck KGaA, Thermo Fisher Scientific Inc. and Applikon Biotechnology BV – Notable Market Participants in Bioreactors Market
The bioreactors market is highly competitive in nature with considerable number of players, having a high level of consolidation overall revenue share. Most of the companies operating in the bioreactors market are present globally and have wide distribution and sales network through partnerships or authorized dealers.
The most notable market participants are Thermo Fisher Scientific Inc., Applikon Biotechnology BV, Merck KGaA, Sartorius AG, Eppendorf, General Electric, Bioengineering AG, Solaris Biotechnology Srl, Danaher (Pall Corporation), and Praj Industries occupying a considerable share of the market owing to their offerings to the market.
Market leaders are involved in extensive research for the development of new products and offerings with advanced technology. For instance, in 2017 Millipore Sigma along with Avid Bioservices announced that Avid Bioservices is likely to upgrade its Myford clinical and commercial manufacturing facility with multiple Mobius 2000-L single-use bioreactors of MilliporeSigma. Similarly, in 2017 Merck announced that BioInvent International AB is looking forward to upgrade and expand its drug manufacturing facility with the use of Merck’s Mobius single-use bioreactors.
| Year | News | Region |
| 2018 | Bioengineering opened its new branch-office in South Korea. This has helped the company to have a strong presence in the Asian countries. | Europe |
| 2017 | Solaris Biotech launched its presence in the USA in the San Francisco Bay Area. The expansion is aimed to provide better service and customer support and to address the rising demand in the US market. | Europe |
| 2018 | Pall Corporation introduced iCELLis Nano bioreactor system to make process development and small scale production of virus for vaccines or gene therapy easy and straightforward. | North America |
| 2017 | Sartorius Stedim Biotech, signed an agreement with Nova Biomedical (US) for the integration of BioProfile FLEX2 into the ambr multi-parallel bioreactor systems for automated, at-line cell culture analytics. The agreement aims biopharmaceutical companies for developing well-characterized cell culture processes in less time while preventing the process development bottleneck being shifted to the analytical laboratory | Europe |
